相关实验视频
Updated: Jul 16, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
397
作为一种新型的免疫调节剂,ICOS/ICOSL相互作用的第一类小分子抑制剂作为一种新型的免疫调节剂
Somaya A Abdel-Rahman1,2, Katarzyna Świderek3, Moustafa T Gabr1
1Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine New York NY 10065 USA mog4005@med.cornell.edu.
RSC medicinal chemistry
|September 21, 2023
概括
研究人员开发了一种新的测定方法,以找到准ICOS/ICOSL通路的小分子,这在T细胞淋巴瘤和免疫抑制中至关重要. AG-120-X成为了一种有前途的第一类抑制剂,为新的癌症疗法铺平了道路.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 诱导性共刺激器 (ICOS) 和其连接体 (ICOSL) 途径对T细胞功能至关重要,并通过调节性T细胞 (Tregs) 参与T细胞淋巴瘤和免疫抑制.
- 目前针对ICOS/ICOSL相互作用的治疗策略仅限于单克隆抗体,缺乏小分子抑制剂.
- 这意味着对ICOS/ICOSL介导疾病的替代治疗方式的巨大未满足需求.
研究的目的:
- 开发和验证一种用于选抑制ICOS/ICOSL相互作用的小分子的新型试验.
- 确定和描述ICOS/ICOSL路径的第一个小分子抑制剂.
- 阐明已识别的抑制剂的作用机制.
主要方法:
- 开发一种时间解析的光共振能量转移 (TR-FRET) 试验,用于评估ICOS/ICOSL相互作用的小分子抑制剂.
- 使用开发的TR-FRET试验,对一个聚焦化学库进行高通量选 (HTS).
- 计算研究包括对接和分子动力学 (MD) 模拟来预测结合机制.
- 结构-活性关系 (SAR) 分析以优化抑制剂功效.
- 生物发光细胞检测证实了目标在共同培养系统中的参与.
主要成果:
- 首个TR-FRET试验用于量化小分子抑制ICOS/ICOSL相互作用的成功建立.
- 高通量查发现AG-120是ICOS/ICOSL相互作用的第一类抑制剂.
- 在TR-FRET试验中,AG-120-X是一种优化的衍生品,在TR-FRET试验中表现出4.68±0.47μM的IC50强烈抑制.
- 在细胞共同培养模型中,AG-120-X表现出ICOS/ICOSL相互作用的剂量依赖抑制.
结论:
- 开发的TR-FRET试验为发现ICOS/ICOSL通路的小分子抑制剂提供了一个强大的平台.
- AG-120-X代表了一种新的,第一类的ICOS/ICOSL相互作用的小分子抑制剂.
- 这些发现为开发针对癌症和其他疾病的ICOS/ICOSL的小分子疗法开辟了新的途径.
相关概念视频
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Immunoglobulin-like Cell Adhesion Molecules
3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

